Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

December 12, 2023

From AstraZeneca

Via Business Wire

AstraZeneca advances scientific leadership in hematology at ASH 2023

November 29, 2023

From AstraZeneca

Via Business Wire

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

November 20, 2023

From AstraZeneca

Via Business Wire

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

November 17, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

November 09, 2023

From AstraZeneca

Via Business Wire

AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity

November 08, 2023

From AstraZeneca

Via Business Wire

Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial

November 03, 2023

From AstraZeneca

Via Business Wire

US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)

October 24, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

October 23, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

October 23, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

October 23, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial

October 22, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

October 21, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

October 21, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone

October 20, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

October 16, 2023

From AstraZeneca

Via Business Wire

AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge

October 12, 2023

From AstraZeneca

Via Business Wire

AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO

October 11, 2023

From AstraZeneca

Via Business Wire

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

September 22, 2023

From AstraZeneca

Via Business Wire

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment

September 14, 2023

From AstraZeneca

Via Business Wire

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

September 11, 2023

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

September 11, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial

September 11, 2023

From AstraZeneca

Via Business Wire

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

August 25, 2023

From AstraZeneca

Via Business Wire

AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030

August 16, 2023

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

July 27, 2023

From AstraZeneca

Via Business Wire

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

July 03, 2023

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial

June 29, 2023

From AstraZeneca

Via Business Wire

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

June 28, 2023

From AstraZeneca

Via Business Wire

AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites

June 13, 2023

From AstraZeneca

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.